Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. März 2026 07:00 ET | Quelle: Vima Therapeutics

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst...
29. Mai 2025 07:30 ET | Quelle: Vima Therapeutics

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being...